<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018225</url>
  </required_header>
  <id_info>
    <org_study_id>CRC090001</org_study_id>
    <nct_id>NCT01018225</nct_id>
  </id_info>
  <brief_title>Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cognitive Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of&#xD;
      moderate to severe nocturia in patients with overactive bladder and who do not have&#xD;
      non-urologic causes of nocturia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was cancelled due to lack of enrollment&#xD;
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>darifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darifenacin</intervention_name>
    <description>7.5 or 15 mg darifenacin, once a day for 6 weeks</description>
    <arm_group_label>darifenacin</arm_group_label>
    <other_name>Enablex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill, once a day, for six weeks</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be aged 21-70, inclusive.&#xD;
&#xD;
          -  Subject mush have given written, personally signed and dated informed consent.&#xD;
&#xD;
          -  Subject must be diagnosed with overactive bladder.&#xD;
&#xD;
          -  Subject must have a nocturia frequency of greater than or equal to 3 episodes a night.&#xD;
&#xD;
          -  Subject must be male or non-pregnant, non-lactating female who agrees to comply with&#xD;
             applicable contraceptive requirements.&#xD;
&#xD;
          -  Subject understands and is able, will a nd and likely to fully comply with study&#xD;
             procedures and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has any concurrent chronic or acute illness or unstable medical condition&#xD;
             either treated or untreated that could confound the results of safety assessments,&#xD;
             increase risk to the subject or lead to difficulty complying with the protocol.&#xD;
&#xD;
          -  The subject has a known or suspected allergy, hypersensitivity, or other medical&#xD;
             contraindications to darifenacin (Enablex®) (or its components).&#xD;
&#xD;
          -  The subject has concomitant diseases in which the use of anticholinergic drugs is&#xD;
             contraindicated, e.g. urinary retention, bladder obstruction, gastric retention and&#xD;
             other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle&#xD;
             glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe&#xD;
             ulcerative colitis, toxic megacolon, and patients who are at risk for these&#xD;
             conditions.&#xD;
&#xD;
          -  Subject is taking another drug which is considered to have significant anticholinergic&#xD;
             activity.&#xD;
&#xD;
          -  Use of drugs known to effect cognition, alertness or drowsiness, such as&#xD;
             benzodiazepines, sedating antihistamines, opioids, or other sedative hypnotic drugs.&#xD;
&#xD;
          -  Subject has moderate to severe obstructive sleep apnea (Apnea/Hypopnea Index ≥ 15)&#xD;
&#xD;
          -  Subject has a medical condition other than OAB that is the most likely cause of the&#xD;
             subject's nocturia (e.g., primary sleep disorder, polydipsia, polyuria).&#xD;
&#xD;
          -  Subject has taken another investigational drug or taken part in a clinical trial&#xD;
             within the last 30 days prior to Screening.&#xD;
&#xD;
          -  The female subject is pregnant or lactating.&#xD;
&#xD;
          -  Subjects with a urine drug screen positive for stimulants, barbiturates,&#xD;
             hallucinogens, opiates, cocaine, cannabis, or amphetamines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

